BMS-641988 has comparable AR-binding affinity with proxalutamide and has shown an antitumor effect superior to bicalutamide in CWR22-BMSLD1 and LNCaP tumor xenograft models [46, 47]. The gene discussed is AR; the disease is neoplasm.